Clinical Trial Update: A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old [Phase 3]

View source ↗

Summary

Phase 3 study assessing the immunogenicity of the Ad26.RSV.preF-based vaccine for respiratory syncytial virus in adults aged 60–75; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF-based vaccine (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Virus Prevention | Phase 3 | Status: COMPLETED | Results posted: 2023-09-11